Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Instagram Outage Disrupts Thousands of U.S. Users 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
